Drug intelligence / Profile preview

streptococcus thermophilus + lactobacillus acidophilus + bifidobacterium longum

Development stage: Preclinical
Lead developer: Kibow Biotech
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

A probiotic combination consisting of three bacterial strains: *Streptococcus thermophilus*, *Lactobacillus acidophilus*, and *Bifidobacterium longum*. Primarily developed and marketed by Kibow Biotech under the brand name Renadyl, this formulation is designed to modulate the gut-kidney axis. The probiotics utilize uremic toxins—such as urea, uric acid, and creatinine—as nutrients for their growth within the gastrointestinal tract. These toxins are then eliminated through the stool, thereby reducing their concentration in the bloodstream. This mechanism is intended to delay the progression of chronic kidney disease (CKD) and improve the quality of life for patients in early to late stages of kidney dysfunction. Additionally, the combination is used as a dietary supplement to maintain healthy gut microbiota, manage symptoms of irritable bowel syndrome (IBS), and support immune function.

Brand names: Renadyl
Other names: Kibow Biotics

Beyond the preview

Go deeper on streptococcus thermophilus + lactobacillus acidophilus + bifidobacterium longum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on streptococcus thermophilus + lactobacillus acidophilus + bifidobacterium longum.

Explore the full profile